2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 265-268
Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Biological Processes, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, Non-Hodgkin Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult
PAPER

375 Nanobody-derived CD19/CD22 tandem CAR T-cell therapy for immune-refractory B-ALL after blinatumomab, inotuzumab, or single-target CAR T-cell therapy: The Phase II nanotrident-2 study

Yihan Yang, MD, Meng Lv, M.D Ph.D2, Zhao Ting3, Ying Wu, MD4, Jing Liu, M.D Ph.D5, Xu-Ying Pei6, Yingxi Zuo7, Yifei Cheng8, Xiao-Dong Mo, MD9, Yuqian Sun, MD10, Yu Wang11, Lanping Xu, MD12, Xiaohui Zhang, MD13, Xiangyu Zhao, MD, PhD14, Xiaojun Huang, MD,PhD15
1 Peking University People's Hospital, Beijing, China
2 Peking University People's Hospital, Beijing, China
3 Peking University People's Hospital, Beijing, China
4 Peking University People's Hospital, Beijing, China
5 Peking University People's Hospital, Beijing, China
6 Peking University People's Hospital, Beijing, China
7 Peking University People's Hospital, Beijing, China, Qinghe Hospital, Beijing, China
8 Beijing Ludaopei Hematology Hospital, Beijing, China, Peking University People's Hospital, Beijing, China, Qinghe Hospital, Beijing, China
9 Peking University People's Hospital, Beijing, China
10 Beijing Ludaopei Hematology Hospital, Beijing, China, Peking University People's Hospital, Beijing, China
11 Peking University People's Hospital, Beijing, China
12 Peking University People's Hospital, Beijing, China
13 Peking University People's Hospital, Beijing, China
14 Peking University People's Hospital, Beijing, China
15 Peking University People's Hospital, Beijing, China, Peking-Tsinghua Center for Life Sciences, Beijing, China

Background: Emerging data from single-target CAR-T trials, including ZUMA-3, indicate that prior exposure to immune-based therapies may compromise subsequent CAR-T efficacy in R/R B-ALL. As blinatumomab(BiTE), inotuzumab (InO), and prior CD19- or CD22-directed CAR-T are increasingly used, effective salvage strategies for immune-refractory disease remain an unmet clinical need. Simultaneous CD19/CD22 targeting may provide a single therapeutic product capable of treating disease across heterogeneous and evolving antigen-expression profiles, including antigen loss or downregulation after prior immunotherapy.

Methods: Alpaca-derived VHHs comprising one CD19-targeting nanobody and two nanobodies recognizing distinct CD22 epitopes were incorporated into a tandem CAR with a trident-like antigen-recognition architecture (SL0217). Based on a preceding phase I 3+3 dose-escalation study (EBMT 2026 Presidential Symposium), autologous SL0217 at 2.0 × 106 cells/kg was selected as the RP2D. We initiated NanoTRIDENT-2, a prospective, multicenter, open-label, single-arm phase II study (NCT06880913), enrolling patients with R/R B-ALL refractory to or relapsed after ≥1 prior immunotherapy, including BiTE, InO, or single-target CAR-T. The primary endpoint was ORR (CR/CRi/CRh). MRD was assessed by FCM, fusion gene qPCR, and NGS-IgH monthly for 6 months and every 3 months thereafter. EMD was assessed by PET-CT at baseline, M1, M3, and suspected relapse.

Results: As of August 1, 2026, 63 patients were enrolled, of whom 51 received standard FC lymphodepletion followed by SL0217 infusion. Of 12 patients not infused by the cutoff, 1 had manufacturing failure in the setting of very high disease burden, 4 had infusion deferred after achieving ORR with bridging therapy, 1 discontinued because of severe infection, 1 developed rapid progression, and 5 were awaiting their scheduled infusion.

Among 51 infused patients, median age was 36 years, and 31 (60.8%) were male. Patients had received a median of 3 prior lines (range, 2–10). All had failed ≥1 prior immunotherapy: BiTE in 27 (52.9%), InO in 27 (52.9%), and single-target CAR-T in 13 (25.5%); 14 (27.5%) had failed ≥2 modalities, and 25 (49.0%) had prior allo-HSCT. Disease involvement comprised iBM in 21 patients (41.2%), iEMD in 17 (33.3%), and BM+EMD in 13 (25.5%). Among 34 patients with BM involvement, 28 (82.4%) had CD19+/CD22+ disease, 3 (8.8%) had CD19−/CD22+ disease, and 3 (8.8%) had dim or partial antigen expression (CD19dim/CD22+, CD19+/CD22dim, and CD19−/CD22partial; n=1 each). Median BM blasts were 46.3% at enrollment (range, 6.0%–91.0%) and 44.0% before lymphodepletion (range, 6.0%–97.0%).

As of August 1, 2026, 45 patients were included in the D28 efficacy and safety analyses, of whom 3 died before D28. At a median follow-up of 7.1 months, ORR was 91.1% (41/45), including 90.0% (27/30) in BM disease and 96.3% (26/27) in EMD. Among BM responders, 96.2% achieved MRD negativity by all available methods. Ten responders (22.2%) proceeded to subsequent first or second allo-HSCT. Only 3 relapses occurred: 1 CSF-positive CNS relapse at 8.7 months and 2 myeloid lineage-switch relapses, comprising hematologic relapse in KMT2A-rearranged disease at 1.8 months and myeloid sarcoma in ZNF384-rearranged disease at 7.5 months.

The median peak peripheral-blood CAR T-cell level by FCM was 332.5 cells/μL (IQR, 115.5–832.6), reached at 14 days (IQR, 10–14). Median qPCR Cmax was 189,000 copies/μg DNA (IQR, 53,235–300,750), with Tmax at 14 days (IQR, 10–21).

CRS occurred in 41 patients (91.1%): 40 (88.9%) had grade 1–2 CRS and 1 (2.2%) had grade 4 CRS; the latter died from progressive leukemia with pericardial infiltration. ICANS occurred in 3 patients (6.7%), with no grade ≥3 events, and 1 developed TIAN. Grade 3–4 Early-N-ICAHT occurred in 23 (51.1%). IEC-HS occurred in 10 (22.2%), including grade ≥3 in 4 (8.9%). Three patients died within 28 days, from grade 5 IEC-HS, progressive leukemia with pericardial infiltration, and severe intracranial infection (n=1 each). Median DFS and OS were not reached. The 6-month non-HSCT-censored DFS was 83.8% (95% CI, 73.4-95.6%), and 6-month OS was 85.9% (95% CI, 71.1–93.4%).

Conclusions: Nanobody-derived CD19/CD22 tandem CAR-T demonstrated high response rates, deep MRD clearance, and encouraging early survival as salvage therapy for immune-refractory R/R B-ALL after prior immunotherapies. Toxicities were generally manageable, while IEC-HS warrants close monitoring.

Yihan Yang, MD: No relevant conflicts of interest to declare.